All Stories

  1. Larval T Cells Are Functionally Distinct from Adult T Cells in Xenopus laevis
  2. Introduction to the special issue Amphibian immunity: stress, disease and ecoimmunology
  3. The amphibian immune system
  4. Environmental endocrine disruptors and amphibian immunity: A bridge between the thyroid hormone axis and T cell development
  5. Amphibians as a model to study the role of immune cell heterogeneity in host and mycobacterial interactions
  6. Evolution and Potential Subfunctionalization of Duplicated fms-Related Class III Receptor Tyrosine Kinase flt3s and Their Ligands in the Allotetraploid Xenopus laevis
  7. γδ T, NKT, and MAIT Cells During Evolution: Redundancy or Specialized Functions?
  8. Virus-Targeted Transcriptomic Analyses Implicate Ranaviral Interaction with Host Interferon Response in Frog Virus 3-Infected Frog Tissues
  9. TLR5-Mediated Reactivation of Quiescent Ranavirus FV3 in Xenopus Peritoneal Macrophages
  10. Virus-Targeted Transcriptomic Analyses Implicate Ranaviral Interaction with Host Interferon Response in Frog Virus 3-infected Frog Tissues
  11. Thyroid Disrupting Chemicals in Mixture Perturb Thymocyte Differentiation in Xenopus laevis Tadpoles
  12. Developing Tadpole Xenopus laevis as a Comparative Animal Model to Study Mycobacterium abscessus Pathogenicity
  13. Immunological Aspects of Chytridiomycosis
  14. Introduction
  15. Evolutionary Underpinnings of Innate-Like T Cell Interactions with Cancer
  16. Impacts of the MHC class I-like XNC10 and innate-like T cells on tumor tolerance and rejection in the amphibian Xenopus
  17. Developmental exposure to chemicals associated with unconventional oil and gas extraction alters immune homeostasis and viral immunity of the amphibian Xenopus
  18. Critical Role of an MHC Class I-Like/Innate-Like T Cell Immune Surveillance System in Host Defense against Ranavirus (Frog Virus 3) Infection
  19. Developmental Exposure to a Mixture of 23 Chemicals Associated With Unconventional Oil and Gas Operations Alters the Immune System of Mice
  20. Distinct MHC class I-like interacting invariant T cell lineage at the forefront of mycobacterial immunity uncovered in Xenopus
  21. Frog's DCs have it all in one
  22. RNAi-Mediated Loss of Function of Xenopus Immune Genes by Transgenesis
  23. An Ancestral Immune Surveillance System in the Amphibian Xenopus Connecting Certain Heat Shock Proteins with Classical and Nonclassical MHC Class I Molecules
  24. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours
  25. Xenopus-FV3 host-pathogen interactions and immune evasion
  26. Collagen-Embedded Tumor Transplantations in Xenopus laevis Tadpoles
  27. Exploring the functions of nonclassical MHC class Ib genes in Xenopus laevis by the CRISPR/Cas9 system
  28. Long term effects of carbaryl exposure on antiviral immune responses in Xenopus laevis
  29. Clinical impact of extensive molecular profiling in advanced cancer patients
  30. Evolutionary Aspects of Macrophages Polarization
  31. Evolutionary Perspective of Tumorigenesis and Antitumor Immunity: A Comparative Approach
  32. Genome evolution in the allotetraploid frog Xenopus laevis
  33. Recombinant Ranaviruses for Studying Evolution of Host–Pathogen Interactions in Ectothermic Vertebrates
  34. Evolution of innate-like T cells and their selection by MHC class I-like molecules
  35. Amphibian macrophage development and antiviral defenses
  36. Preface to the special issue “Hematopoiesis and immunity”
  37. Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients
  38. Frog Virus 3 dissemination in the brain of tadpoles, but not in adult Xenopus, involves blood brain barrier dysfunction
  39. Ouro proteins are not essential to tail regression during Xenopus tropicalis metamorphosis
  40. A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy
  41. Xenopus tumor model
  42. Xenopus in vivo imaging of inflammation
  43. Characterization of Frog Virus 3 knockout mutants lacking putative virulence genes
  44. Retention of duplicated ITAM-containing transmembrane signaling subunits in the tetraploid amphibian species Xenopus laevis
  45. Nonclassical MHC-Restricted Invariant Vα6 T Cells Are Critical for Efficient Early Innate Antiviral Immunity in the Amphibian Xenopus laevis
  46. Distinct functional roles of amphibian (Xenopus laevis) colony-stimulating factor-1- and interleukin-34-derived macrophages
  47. Renouvellement des cellules souches et épidémiologie des cancers – À propos d’un article de Tomasetti et Vogelstein paru dans Science
  48. Xenopus laevis tadpoles anti-FV3 IFNλ response
  49. Ranavirus Host Immunity and Immune Evasion
  50. Inflammation-Mediated FV3 Reactivation
  51. Negative effects of low dose atrazine exposure on the development of effective immunity to FV3 in Xenopus laevis
  52. On the use of pharmacogenetics in cancer treatment and clinical trials
  53. Divergent antiviral roles of amphibian (Xenopus laevis) macrophages elicited by colony-stimulating factor-1 and interleukin-34
  54. Ciblage de mTOR et identification de «répondeurs exceptionnels»
  55. Evolution of nonclassical MHC-dependent invariant T cells
  56. Environmental dependency of amphibian–ranavirus genotypic interactions: evolutionary perspectives on infectious diseases
  57. A prominent role for invariant T cells in the amphibian Xenopus laevis tadpoles
  58. Differential transcription of fathead minnow immune-related genes following infection with frog virus 3, an emerging pathogen of ectothermic vertebrates
  59. A critical role of non-classical MHC in tumor immune evasion in the amphibian Xenopus model
  60. Unusual evolutionary conservation and further species-specific adaptations of a large family of nonclassical MHC class Ib genes across different degrees of genome ploidy in the amphibian subfamily Xenopodinae
  61. FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
  62. No association between XRCC3 Thr241Met and XPD Lys751Gln polymorphisms and the risk of colorectal cancer in West Algerian population: a case–control study
  63. Amphibian IFN responses to the ranavirus FV3
  64. A functionalized heterobimetallic99mTc/Re complex as a potential dual-modality imaging probe: synthesis, photophysical properties, cytotoxicity and cellular imaging investigations
  65. Mechanisms of amphibian macrophage development: characterization of the Xenopus laevis colony-stimulating factor-1 receptor
  66. Cytotoxic effect of chlorpyrifos ethyl and its degradation derivatives by Pseudomonas peli strain isolated from the Oued Hamdoun River (Tunisia)
  67. Evaluation of antiproliferative and antioxidant activities of the organic extract and its polar fractions from the Mediterranean gorgonian Eunicella singularis
  68. Xenopus Class Ib-restricted iT cells
  69. Recent Research Progress and Potential Uses of the Amphibian Xenopus as a Biomedical and Immunological Model System
  70. Antitumor activity of semisynthetic derivatives of Aconitum alkaloids
  71. Antiproliferative activity and phenolics of the Mediterranean seaweed Laurencia obusta
  72. Biologie de la métastase
  73. Decolorization does not always mean detoxification: case study of a newly isolated Pseudomonas peli for decolorization of textile wastewater
  74. Effective RNAi-mediated  2-microglobulin loss of function by transgenesis in Xenopus laevis
  75. Xenopus liver macrophage precursors
  76. Short curcumin treatment modulates oxidative stress, arginase activity, aberrant crypt foci, and TGF-β1 and HES-1 transcripts in 1,2-dimethylhydrazine-colon carcinogenesis in mice
  77. R4 regulators of G protein signaling (RGS) identify an ancient MHC-linked synteny group
  78. Susceptibility of Xenopus laevis tadpoles to infection by the ranavirus Frog-Virus 3 correlates with a reduced and delayed innate immune response in comparison with adult frogs
  79. Gene Expression Signature Predicting High-Grade Prostate Cancer Responses to Oxaliplatin
  80. Hemisynthesis and antiproliferative properties of mono-[O-(14-benzoylaconine-8-yl)]esters and bis-[O-(14-benzoylaconine-8-yl)]esters
  81. Immune Evasion Strategies of Ranaviruses and Innate Immune Responses to These Emerging Pathogens
  82. Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients
  83. Anti‐Inflammatory and Antiproliferative Activities of Organic Fractions from the Mediterranean Brown Seaweed, Cystoseira Compressa
  84. Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity
  85. “Ranaviruses: An emerging threat to ectothermic vertebrates” Report of the First International Symposium on Ranaviruses, Minneapolis MN July 8, 2011
  86. Evaluation of antiproliferative and anti-inflammatory activities of methanol extract and its fractions from the Mediterranean sponge
  87. Optimized transgenesis in Xenopus laevis/gilli isogenetic clones for immunological studies
  88. Anti-inflammatory, anti-proliferative and anti-oxidant activities of organic extracts from the Mediterranean seaweed, Cystoseira crinita
  89. Ranavirus: past, present and future
  90. Médicaments anticancéreux : de la chimiothérapie cytotoxique aux thérapies ciblées
  91. Les inhibiteurs de tyrosine kinase
  92. Antiviral Immunity in Amphibians
  93. Waterborne infectivity of the Ranavirus frog virus 3 in Xenopus laevis
  94. The genus Xenopus as a multispecies model for evolutionary and comparative immunobiology of the 21st century
  95. Comparative Study of Skin Graft Tolerance and Rejection in the Frog Xenopus Laevis
  96. Improved Knockout Methodology Reveals That Frog Virus 3 Mutants Lacking either the 18K Immediate-Early Gene or the Truncated vIF-2  Gene Are Defective for Replication and Growth In Vivo
  97. Encapsulation of Docetaxel into PEGylated Gold Nanoparticles for Vectorization to Cancer Cells
  98. La pollution atmosphérique, cause de cancer bronchique ?
  99. Ecology of Viruses Infecting Ectothermic Vertebrates-The Impact of Ranavirus Infections on Amphibians
  100. ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
  101. Phylogenetic and developmental study of CD4, CD8 α and β T cell co-receptor homologs in two amphibian species, Xenopus tropicalis and Xenopus laevis
  102. Présentation générale des mécanismes de réparation de l'ADN
  103. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma
  104. Vers une prescription individualisée des traitements anticancéreux
  105. Remarkable Conservation of Distinct Nonclassical MHC Class I Lineages in Divergent Amphibian Species
  106. Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models
  107. Signalisation cellulaire et cancer
  108. Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins
  109. Comparative in vivo Study of gp96 Adjuvanticity in the Frog Xenopus laevis
  110. Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates
  111. Phylogeny, genomic organization and expression of λ and κ immunoglobulin light chain genes in a reptile, Anolis carolinensis
  112. The Genome of the Western Clawed Frog Xenopus tropicalis
  113. Innate Immune Responses and Permissiveness to Ranavirus Infection of Peritoneal Leukocytes in the Frog Xenopus laevis
  114. The amphibians Xenopus laevis and Silurana tropicalis possess a family of activating KIR-related Immunoglobulin-like Receptors
  115. Emerging Ranaviral Infectious Diseases and Amphibian Decline
  116. Expression Profiling the Temperature-Dependent Amphibian Response to Infection by Batrachochytrium dendrobatidis
  117. Mass mortality associated with a frog virus 3- like Ranavirus infection in farmed tadpoles Rana catesbeiana from Brazil
  118. Control of asthma in children: still unacceptable? A French cross-sectional study
  119. Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model
  120. Genome-Wide Transcriptional Response of Silurana (Xenopus) tropicalis to Infection with the Deadly Chytrid Fungus
  121. ABC Transporters and Multidrug Resistance
  122. The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models
  123. Isolation of a Latimeria menadoensis heat shock protein 70 (Lmhsp70) that has all the features of an inducible gene and encodes a functional molecular chaperone
  124. Current knowledge of the immune system of the amphibian Xenopus.
  125. Xenopus, a unique comparative model to explore the role of certain heat shock proteins and non-classical MHC class Ib gene products in immune surveillance
  126. Tumorigenesis and anti-tumor immune responses in Xenopus
  127. In vivo and in vitro techniques for comparative study of antiviral T-cell responses in the amphibian Xenopus
  128. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
  129. Impact of EGFR Gene Polymorphisms on Anticancer Drug Cytotoxicity In Vitro
  130. A chemotherapy-associated senescence bystander effect in breast cancer cells
  131. Synthesis and antiproliferative activity of aryl- and heteroaryl-hydrazones derived from xanthone carbaldehydes
  132. The Xenopus FcR family demonstrates continually high diversification of paired receptors in vertebrate evolution
  133. Protein arginine (N)‐methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins
  134. Phylogenetic Conservation of Glycoprotein 96 Ability to Interact with CD91 and Facilitate Antigen Cross-Presentation
  135. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome
  136. Localization and Differential Expression of Activation-Induced Cytidine Deaminase in the Amphibian Xenopus upon Antigen Stimulation and during Early Development
  137. Les poisons du fuseau
  138. XENOPUS LAEVIS: A POSSIBLE VECTOR OF RANAVIRUS INFECTION?
  139. Conservation of IL‐6 trans‐signaling mechanisms controlling L‐selectin adhesion by fever‐range thermal stress
  140. Involvement of nonclassical MHC class Ib molecules in heat shock protein‐mediated anti‐tumor responses
  141. Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene
  142. Inhibition of Topoisomerase I Cleavage Activity by Thiol-reactive Compounds
  143. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors
  144. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel
  145. Prédiction de la réponse aux anticancéreux par analyse du transcriptome
  146. Techniques de recherche des polymorphismes génétiques
  147. In Vivo Study of T-Cell Responses to Skin Alloantigens in Xenopus Using a Novel Whole-Mount Immunohistology Method
  148. A phase II study for the evaluation of quinine as a modulator of multidrug resistance in non-Hodgkin’s lymphoma
  149. Characterization of Primary and Memory CD8 T-Cell Responses against Ranavirus (FV3) in Xenopus laevis
  150. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls
  151. Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines
  152. Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel
  153. A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours
  154. Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients
  155. Structural Phylogenetic Analysis of Activation-Induced Deaminase Function
  156. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells
  157. Experimental study of dexrazoxane–anthracycline combinations using the model of isolated perfused rat heart
  158. Generation of a long-lasting, protective, and neutralizing antibody response to the ranavirus FV3 by the frog Xenopus
  159. 8-O-Azeloyl-14-benzoylaconine: A new alkaloid from the roots of Aconitum karacolicum Rapcs and its antiproliferative activities
  160. Major improvement of the reference method of the French drug resistance network for P-glycoprotein detection in human haematological malignancies
  161. Predicting drug response and toxicity based on gene polymorphisms
  162. Pharmacog�n�tique?pharmacog�nomie, quelle est la diff�rence?
  163. Pharmacogenetics of MDR family proteins
  164. Pharmacog�n�tique de l?irinot�can: la carboxylest�rase 2
  165. Prediction of anticancer drug response by transcriptome analysis. The new pathways of pharmacogenomics
  166. Techniques de recherche des polymorphismes génétiques
  167. Adaptive immunity and histopathology in frog virus 3-infected Xenopus
  168. CD91 up-regulates upon immune stimulation in Xenopus adult but not larval peritoneal leukocytes
  169. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38
  170. Phylogenetic Conservation of gp96-Mediated Antigen-Specific Cellular Immunity: New Evidence from Adoptive Cell Transfer in Xenopus
  171. Predicting drug response based on gene expression
  172. Anti‐tumor MHC class Ia‐unrestricted CD8 T cell cytotoxicity elicited by the heat shock protein gp96
  173. Pharmacogénétique et pharmacogénomique des cancers
  174. Xenopus as an experimental model for studying evolution of hsp–immune system interactions
  175. Molecular Determinants of the Cytotoxicity of Platinum Compounds
  176. Multidrug Resistance Reversal Agents
  177. Signaling FcRγ and TCRζ subunit homologs in the amphibian Xenopus laevis
  178. Ontogeny of Xenopus NK cells in the absence of MHC class I antigens
  179. DNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer
  180. Development and characterization of a model system to study amphibian immune responses to iridoviruses
  181. Evolution of heat shock protein and immunity
  182. Bacterial stimulation upregulates the surface expression of the stress protein gp96 on B cells in the frog Xenopus
  183. Identification and characterization of Xenopus CD8+ T cells expressing an NK cell-associated molecule
  184. Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan: Figure 1
  185. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines
  186. Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes
  187. Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells
  188. Minor Histocompatibility Antigen-Specific MHC-Restricted CD8 T Cell Responses Elicited by Heat Shock Proteins
  189. MHC-RESTRICTED AND -UNRESTRICTED CD8 T CELLS
  190. Metabolism of methoxymorpholino‐doxorubicin in rat, dog and monkey liver microsomes: comparison with human microsomes
  191. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants
  192. Resistance to cytotoxic agents
  193. Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver
  194. Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome
  195. In vitro thymocyte differentiation in MHC class I-negative Xenopus larvae
  196. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines
  197. Down-regulation of bcr-abl and bcl-xL expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors
  198. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia
  199. B‐cell development in the amphibian Xenopus
  200. B-cell development in the amphibian Xenopus
  201. New targets, new drugs
  202. Preclinical Evaluation of the Cardiotoxicity of Taxane–Anthracycline Combinations Using the Model of Isolated Perfused Rat Heart
  203. Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance
  204. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients
  205. Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin
  206. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model
  207. Multidrug resistance in oncology: diagnostic and therapeutic approaches
  208. In vitro differentiation of a CD4/CD8 double-positive equivalent thymocyte subset in adult Xenopus
  209. Ontogeny of CTX expression in xenopus
  210. Evolution of immune surveillance and tumor immunity: studies in Xenopus
  211. Resistance to Anticancer Drugs: Are We Ready to Use Biologic Information for the Treatment of Patients With Cancer?
  212. Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy
  213. Approaches to multidrug resistance reversal
  214. Doxorubicin-Induced Alterations of c-myc and c-jun Gene Expression in Rat Glioblastoma Cells: Role of c-jun in Drug Resistance and Cell Death
  215. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.
  216. Determination of unbound platinum after oxaliplatin administration
  217. Transcriptional down-regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine
  218. Genealogical study of oculopharyngeal muscular dystrophy in France
  219. Antibody Cross-Linking of the Thymocyte-Specific Cell Surface Molecule CTX Causes Abnormal Mitosis and Multinucleation of Tumor Cells
  220. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate forms
  221. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin
  222. Confocal microscopy of idarubicin localisation
  223. French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours
  224. Multicentric evaluation of the MDR phenotype in leukemia
  225. Differential Stabilization of Topoisomerase‐II–DNA Cleavable Complexes by Doxorubicin and Etoposide in Doxorubicin‐Resistant Rat Glioblastoma Cells
  226. Cross-linking CTX, a novel thymocyte-specific molecule, inhibits the growth of lymphoid tumor cells in xenopus
  227. Glucuronidation of SN‐38, the Active Metabolite of Irinotecan, by Human Hepatic Microsomes
  228. Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation
  229. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver Carboxylesterase
  230. Effects of modulators of multidrug resistance on the expression of the MDR1 gene in human KB cells in culture
  231. Semisynthesis of RPR 121056A, a major metabolite of irinotecan (CPT-11)
  232. CTX, a novel molecule specifically expressed on the surface of cortical thymocytes inXenopus
  233. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention
  234. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance
  235. Xenopus lymphoid tumor cell lines
  236. Xenopus lymphoid tumor cell lines
  237. Ontogeny of the alloimmune response against a transplanted tumor in Xenopus laevis
  238. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line
  239. A Xenopus lymphoid tumor cell line with complete Ig genes rearrangements and T-cell characteristics
  240. Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line
  241. Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines
  242. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin
  243. Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells
  244. Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan
  245. Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives
  246. Pharmacological Properties of Oral Idarubicin
  247. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma
  248. Intracellural accretion of free and nanosphere-encapsulated doxorubicin
  249. Clinical Pharmacokinetics of Epirubicin
  250. Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil
  251. Individual dose adaptation of anticancer drugs
  252. Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance
  253. Expression of MDR1/P glycoprotein in human sarcomas
  254. Lymphoid Tumors of Xenopus laevis with Different Capacities for Growth in Larvae and Adults
  255. Differential over‐expression of mdr1 genes in multidrug‐resistant rat glioblastoma cell lines selected with doxorubicin or vincristine
  256. Doxorubicin‐induced oxygen free radical formation in sensitive and doxorubicin‐ resistant variants of rat glioblastoma cell lines
  257. Doxorubicin‐induced oxygen free radical formation in sensitive and doxorubicin‐resistant variants of rat glioblastoma cell lines
  258. Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines
  259. Doxorubicin‐induced oxygen free radical formation in sensitive and doxorubicin‐resistant variants of rat glioblastoma cell lines
  260. Aspects of the cellular pharmacology of N-l-leucyldoxorubicin in human tumor cell lines
  261. Clinical Pharmacokinetics of Idarubicin
  262. Diffusion of a particular 4.1(−) hereditary elliptocytosis allele in the French northern Alps
  263. Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-hodgkin's lymphoma
  264. Doxorubicin‐induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin
  265. Epirubicin
  266. New drug design and development in cancer: present status and future perspectives
  267. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells
  268. Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines
  269. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
  270. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines
  271. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients
  272. Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities
  273. Measurement of doxorubicin-induced lipid peroxidation under the conditions that determine cytotoxicity in cultured tumor cells
  274. Drug resistance in oncology: from concepts to applications
  275. In Vitro Growth of Thymic Tumor Cell Lines fromXenopus
  276. An abnormal concentration of cases of Rendu-Osler disease in the Valserine valley of the French Jura: a genealogical and demographic study
  277. Variability in the pharmacokinetics of epirubicin: a population analysis
  278. AXenopus laeviscreatine kinase isozyme (CK-III/III) expressed preferentially in larval striated muscle: cDNA sequence, developmental expression and subcellular immunolocalization
  279. Limited sampling models for doxorubicin pharmacokinetics.
  280. Differential expression of creatine kinase isozymes during development of Xenopus laevis: An unusual heterodimeric isozyme appears at metamorphosis
  281. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients
  282. Shifts in interleukin-4 and interferon-γ production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis
  283. Fraser syndrome with renal agenesis in two consanguineous Turkish families
  284. Influence of trimetazidine on deleterious effect of oxygen radical species in post-ischemic acute renal failure in the rat
  285. Cellular pharmacology of 4'-iodo-4'-deoxydoxorubicin
  286. Development of Mechanisms of Protection Against Oxidative Stress in Doxorubicin-Resistant Rat Tumoral Cells in Culture
  287. Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug
  288. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture
  289. Assessment of the experimental model of transplanted C6 glioblastoma in wistar rats
  290. Age‐related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population
  291. Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients
  292. DUCHENNE MUSCULAR DYSTROPHY: NEONATAL SCREENING AND PRENATAL DIAGNOSIS
  293. Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells
  294. Alteration of ganglioside composition and metabolism in doxorubicin-resistant rat tumoral cells
  295. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes
  296. Purification and characterization of cytoplasmic creatine kinase isozymes ofXenopus laevis
  297. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients
  298. The reversal of doxorubicin resistance by verapamil is not due to an effect on calcium channels
  299. Purification and characterization of a casein‐kinase‐II‐type enzyme from Xenopus laevis ovary
  300. Free fatty acid uptake is increased in doxorubicin-resistant glioblastoma cells
  301. Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated prefused rat liver
  302. Pharmacokinetics of doxorubicin in sarcoma patients
  303. Continuous Infusion or Intravenous Bolus: What Is the Rationale for Doxorubicin Administration?
  304. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients
  305. Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture
  306. Hepatic metabolism of doxorubicin in mice and rats
  307. Fluorescence anisotropy of kidney lipids and membranes of a hibernating mammal
  308. Cellular Pharmacology of Doxorubicin in Sensitive and Resistant Rat Glioblastoma Cells in Culture
  309. Evaluation of Drug Therapy and Teratogenic Risk in a Rhone-Alpes District Population of Pregnant Epileptic Women
  310. Tentative dose-monitoring of doxorubicin in lymphoma patients
  311. Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients
  312. Incorporation and turnover of phospholipid precursors in normal and tumoral glial cells in culture
  313. Fluorescence polarization study of lipids and membranes prepared from brain hemispheres of a hibernating mammal
  314. Cellular Pharmacokinetics of Doxorubicin in Cultured Mouse Sarcoma Cells Originating from Autochthonous Tumors
  315. Incorporation and metabolism of exogenous fatty acids by cultured normal and tumoral glial cells
  316. Early-phase pharmacokinetics of doxorubicin in non-hodgkin lymphoma patients
  317. Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells
  318. Pharmacokinetics of adriamycin in patients with breast cancer: Correlation between pharmacokinetic parameters and clinical short-term response
  319. Changes in lipid composition of the brain cellular membranes of an hibernating mammal during its circannual rhythm
  320. Rectocolic familial polyposis; a study of 32 cases
  321. Sanfilippo A syndrome (Mucopolysaccharidosis III A): a neurochemical study
  322. Phospholipid acyl group composition in normal and tumoral nerve cells in culture
  323. Uptake of l‐Glutamate and Taurine in Neuroblastoma Cells with Altered Fatty Acid Composition of Membrane Phospholipids
  324. Dynamics of Phospholipids in Cultured Cells of Neural Origin
  325. SYSTEMATIC NEONATAL SCREENING FOR DUCHENNE MUSCULAR DYSTROPHY
  326. UTILIZATION OF POLYUNSATURATED FATTY ACID SUPPLEMENTS BY CULTURED NEUROBLASTOMA CELLS1
  327. Confirmation of the assignment of the human <i>SOD<sub>S</sub> </i>gene to chromosome 21q22
  328. Polar head groups manipulation of phospholipids in cultured neuroblastoma cells
  329. Gangliosides of Active and Inactive Neuroblastoma Clones
  330. Thin-layer chromatography of gangliosides
  331. Essential fatty acid metabolism in cultured astroblasts
  332. IS VARICELLA VIRUS TERATOGENIC?
  333. NEUTRAL LIPIDS AND PHOSPHOLIPIDS FROM CULTURED ASTROBLASTS
  334. Changes in Sugar Composition of Membrane-Bound Glycoproteins during Postnatal Development of Rat Cerebellum
  335. Changes of Ganglioside Pattern during Postnatal Development of Rat Cerebellum
  336. Quantitation of neutral glycolipids by thin-layer chromatography on precoated plates
  337. Gangliosides of glial cells: A comparative study of normal astroblasts in tissue culture and glial cells isolated on sucrose‐ficoll gradients
  338. Pericentric inversion, inv(10), in a mother and aneusomy by recombination, inv(10),rec(10), in her son